EN
Current Location:Home Science & TechnologyResearch Areas

Research Areas

We are a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline and an established commercial-scale in-house manufacturing capability. To address unmet medical needs in the autoimmune and allergic disease drug market in China, which is forecast by Frost & Sullivan to surpass one hundred billion yuan by 2025, we have built a comprehensive pipeline that covers the four major disease areas in the field, including skin, rheumatic,respiratory and digestive diseases.

In the autoimmune and allergic disease field, there are often complex relationships between and among various targets and indications across disease areas. The chart below illustrates the position of our pipeline assets in context.

Skin

  • PS
  • AD
  • PN
  • CSU
  • Pruritus

Rheumatic

  • AS
  • SLE
  • LN

Respiratory

  • CRswNP
  • Asthma
  • COPD

Digestive

  • CD
  • UC
QX001S
IL-I2/IL-23p40
QX002N
IL-17A
QX005N
IL-4Rα
QX004N
IL-23p19
QX006N
IFNAR1
QX008N
TSLP
QX007N
IL-33
QX013N
c-kit
QX010N
IL-31R
Core Product
IND approved
Before IND approved
Not currently in pipeline but we may inverstigate this indication for further indication expansion

According to Frost & Sullivan, among Chinese domestic companies, we had one of the most comprehensive biologic drug pipelines in autoimmune and allergic diseases in terms of the number of IND-approved drug candidates and indications, and also one of the most advanced in terms of the overall development status, as of the Latest Practicable Date.

annotations:*The above information comes from Frost&Sullivan's report.